What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Breast cancer
Marco Colleoni mostly deals with Internal medicine, Breast cancer, Oncology, Surgery and Cancer.
His research combines Gynecology and Internal medicine.
The various areas that Marco Colleoni examines in his Breast cancer study include Clinical endpoint, Disease and Adjuvant therapy.
The concepts of his Oncology study are interwoven with issues in Survival rate, Pathology, Estrogen receptor, Hazard ratio and Survival analysis.
His research in Surgery intersects with topics in Standard treatment, Axillary lymph nodes, Metastasis, Sentinel node and Axilla.
His Cancer study incorporates themes from Combined Modality Therapy and Biopsy.
His most cited work include:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (1828 citations)
- Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98 (771 citations)
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (753 citations)
What are the main themes of his work throughout his whole career to date?
Marco Colleoni spends much of his time researching Internal medicine, Breast cancer, Oncology, Chemotherapy and Cancer.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Gynecology.
His Breast cancer research integrates issues from Clinical trial, Surgery, Disease and Hazard ratio.
His Oncology research is multidisciplinary, incorporating elements of Metastatic breast cancer, Cyclophosphamide, Fluorouracil and Endocrine system.
Marco Colleoni has researched Chemotherapy in several fields, including Regimen and Tolerability.
His Cancer research incorporates themes from Endocrinology and Pathology.
He most often published in these fields:
- Internal medicine (80.53%)
- Breast cancer (70.19%)
- Oncology (65.62%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (80.53%)
- Breast cancer (70.19%)
- Oncology (65.62%)
In recent papers he was focusing on the following fields of study:
Marco Colleoni focuses on Internal medicine, Breast cancer, Oncology, Letrozole and Trastuzumab.
His Randomized controlled trial, Cancer, Adverse effect, Palbociclib and Adjuvant investigations are all subjects of Internal medicine research.
His Breast cancer research is multidisciplinary, relying on both Clinical trial, Cohort, Placebo, Endocrine system and Adjuvant therapy.
His Oncology research incorporates themes from Chemotherapy, Metastatic breast cancer, Hormone receptor, Clinical endpoint and Hazard ratio.
His Letrozole research is multidisciplinary, incorporating perspectives in Neoadjuvant therapy, Estrogen and Urology.
His research in Trastuzumab intersects with topics in Biosimilar, Cardiotoxicity and Early breast cancer.
Between 2018 and 2021, his most popular works were:
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer (239 citations)
- Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019 (154 citations)
- Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. (125 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
His primary areas of study are Breast cancer, Internal medicine, Oncology, Letrozole and Adverse effect.
His Breast cancer research includes themes of Radiation therapy, Surgery, Metastasis, Endocrine system and Adjuvant therapy.
His Placebo research extends to Internal medicine, which is thematically connected.
The study incorporates disciplines such as Cancer, Trastuzumab, Chemotherapy, Randomized controlled trial and Tamoxifen in addition to Oncology.
His research integrates issues of Neoadjuvant therapy, Estrogen receptor, Fulvestrant and Estrogen in his study of Letrozole.
His biological study spans a wide range of topics, including Metastatic breast cancer and Palbociclib.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
